177 related articles for article (PubMed ID: 36120299)
1. Cost-Effectiveness of Pharmacogenomics-Guided Prescribing to Prevent Gene-Drug-Related Deaths: A Decision-Analytic Model.
van der Wouden CH; Marck H; Guchelaar HJ; Swen JJ; van den Hout WB
Front Pharmacol; 2022; 13():918493. PubMed ID: 36120299
[No Abstract] [Full Text] [Related]
2. Cost-utility analysis and cross-country comparison of pharmacogenomics-guided treatment in colorectal cancer patients participating in the U-PGx PREPARE study.
Fragoulakis V; Roncato R; Bignucolo A; Patrinos GP; Toffoli G; Cecchin E; Mitropoulou C
Pharmacol Res; 2023 Nov; 197():106949. PubMed ID: 37802427
[TBL] [Abstract][Full Text] [Related]
3. Pharmacogenomics - a minor rather than major force in clinical medicine.
Polasek TM
Expert Rev Clin Pharmacol; 2024 Mar; 17(3):203-212. PubMed ID: 38307498
[TBL] [Abstract][Full Text] [Related]
4. Clinical implementation of preemptive pharmacogenomics in psychiatry.
Skokou M; Karamperis K; Koufaki MI; Tsermpini EE; Pandi MT; Siamoglou S; Ferentinos P; Bartsakoulia M; Katsila T; Mitropoulou C; Patrinos GP;
EBioMedicine; 2024 Mar; 101():105009. PubMed ID: 38364700
[TBL] [Abstract][Full Text] [Related]
5. Discrepancies and similarities in the genome-informed guidance for psychiatric disorders amongst different regulatory bodies and research consortia using next generation sequencing-based clinical pharmacogenomics data.
Kordou Z; Skokou M; Tsermpini EE; Chantratita W; Fukunaga K; Mushiroda T; Patrinos GP; Koromina M
Pharmacol Res; 2021 May; 167():105538. PubMed ID: 33705851
[TBL] [Abstract][Full Text] [Related]
6. Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction of DPYD and fluoropyrimidines.
Lunenburg CATC; van der Wouden CH; Nijenhuis M; Crommentuijn-van Rhenen MH; de Boer-Veger NJ; Buunk AM; Houwink EJF; Mulder H; Rongen GA; van Schaik RHN; van der Weide J; Wilffert B; Deneer VHM; Swen JJ; Guchelaar HJ
Eur J Hum Genet; 2020 Apr; 28(4):508-517. PubMed ID: 31745289
[TBL] [Abstract][Full Text] [Related]
7. Development of the PGx-Passport: A Panel of Actionable Germline Genetic Variants for Pre-Emptive Pharmacogenetic Testing.
van der Wouden CH; van Rhenen MH; Jama WOM; Ingelman-Sundberg M; Lauschke VM; Konta L; Schwab M; Swen JJ; Guchelaar HJ
Clin Pharmacol Ther; 2019 Oct; 106(4):866-873. PubMed ID: 31038729
[TBL] [Abstract][Full Text] [Related]
8. Drug Use in Denmark for Drugs Having Pharmacogenomics (PGx) Based Dosing Guidelines from CPIC or DPWG for CYP2D6 and CYP2C19 Drug-Gene Pairs: Perspectives for Introducing PGx Test to Polypharmacy Patients.
Westergaard N; Søgaard Nielsen R; Jørgensen S; Vermehren C
J Pers Med; 2020 Jan; 10(1):. PubMed ID: 31963319
[TBL] [Abstract][Full Text] [Related]
9. Systematic review of the evidence on the cost-effectiveness of pharmacogenomics-guided treatment for cardiovascular diseases.
Zhu Y; Swanson KM; Rojas RL; Wang Z; St Sauver JL; Visscher SL; Prokop LJ; Bielinski SJ; Wang L; Weinshilboum R; Borah BJ
Genet Med; 2020 Mar; 22(3):475-486. PubMed ID: 31591509
[TBL] [Abstract][Full Text] [Related]
10. Implementing Pharmacogenetic Testing in Gastrointestinal Cancers (IMPACT-GI): Study Protocol for a Pragmatic Implementation Trial for Establishing
Varughese LA; Bhupathiraju M; Hoffecker G; Terek S; Harr M; Hakonarson H; Cambareri C; Marini J; Landgraf J; Chen J; Kanter G; Lau-Min KS; Massa RC; Damjanov N; Reddy NJ; Oyer RA; Teitelbaum UR; Tuteja S
Front Oncol; 2022; 12():859846. PubMed ID: 35865463
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness analysis of pharmacogenomics-guided clopidogrel treatment in Spanish patients undergoing percutaneous coronary intervention.
Fragoulakis V; Bartsakoulia M; Díaz-Villamarín X; Chalikiopoulou K; Kehagia K; Ramos JGS; Martínez-González LJ; Gkotsi M; Katrali E; Skoufas E; Vozikis A; John A; Ali BR; Wordsworth S; Dávila-Fajardo CL; Katsila T; Patrinos GP; Mitropoulou C
Pharmacogenomics J; 2019 Oct; 19(5):438-445. PubMed ID: 30647444
[TBL] [Abstract][Full Text] [Related]
12. Genotyping for HLA Risk Alleles to Prevent Drug Hypersensitivity Reactions: Impact Analysis.
Manson LEN; van den Hout WB; Guchelaar HJ
Pharmaceuticals (Basel); 2021 Dec; 15(1):. PubMed ID: 35056062
[TBL] [Abstract][Full Text] [Related]
13. Multi-gene Pharmacogenomic Testing That Includes Decision-Support Tools to Guide Medication Selection for Major Depression: A Health Technology Assessment.
Ontario Health (Quality)
Ont Health Technol Assess Ser; 2021; 21(13):1-214. PubMed ID: 34484487
[TBL] [Abstract][Full Text] [Related]
14. Estimating the prevalence of potential and actionable drug-gene interactions in Irish primary care: A cross-sectional study.
Johnson L; Youssef E; O'Shea J; Thornley T; Gallagher J; Ledwidge M; Ryan C
Br J Clin Pharmacol; 2024 Jun; ():. PubMed ID: 38864275
[TBL] [Abstract][Full Text] [Related]
15. Economic Evaluation of Multiple-Pharmacogenes Testing for the Prevention of Adverse Drug Reactions in People Living with HIV.
Turongkaravee S; Praditsitthikorn N; Ngamprasertchai T; Jittikoon J; Mahasirimongkol S; Sukasem C; Udomsinprasert W; Wu O; Chaikledkaew U
Clinicoecon Outcomes Res; 2022; 14():447-463. PubMed ID: 35832304
[TBL] [Abstract][Full Text] [Related]
16. Identifying the prevalence of clinically actionable drug-gene interactions in a health system biorepository to guide pharmacogenetics implementation services.
Pasternak AL; Ward K; Irwin M; Okerberg C; Hayes D; Fritsche L; Zoellner S; Virzi J; Choe HM; Ellingrod V
Clin Transl Sci; 2023 Feb; 16(2):292-304. PubMed ID: 36510710
[TBL] [Abstract][Full Text] [Related]
17. Pharmacist-Initiated Pre-Emptive Pharmacogenetic Panel Testing with Clinical Decision Support in Primary Care: Record of PGx Results and Real-World Impact.
van der Wouden CH; Bank PCD; Özokcu K; Swen JJ; Guchelaar HJ
Genes (Basel); 2019 May; 10(6):. PubMed ID: 31146504
[TBL] [Abstract][Full Text] [Related]
18. Use of Pharmacogenetic Drugs by the Dutch Population.
Alshabeeb MA; Deneer VHM; Khan A; Asselbergs FW
Front Genet; 2019; 10():567. PubMed ID: 31312209
[TBL] [Abstract][Full Text] [Related]
19. A model-based cost-effectiveness analysis of pharmacogenomic panel testing in cardiovascular disease management: preemptive, reactive, or none?
Zhu Y; Moriarty JP; Swanson KM; Takahashi PY; Bielinski SJ; Weinshilboum R; Wang L; Borah BJ
Genet Med; 2021 Mar; 23(3):461-470. PubMed ID: 33041335
[TBL] [Abstract][Full Text] [Related]
20. Pharmacogenetics Guidelines: Overview and Comparison of the DPWG, CPIC, CPNDS, and RNPGx Guidelines.
Abdullah-Koolmees H; van Keulen AM; Nijenhuis M; Deneer VHM
Front Pharmacol; 2020; 11():595219. PubMed ID: 33568995
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
